Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07137689 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
A Phase 1 study of Renal Insufficiency, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 4
- Study locations
NCT07137689 is a Phase 1 study of Renal Insufficiency that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 32 participants, below the 100-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (68% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT07137689, a Phase 1 study of Renal Insufficiency, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to help determine the right dose of LY3537982 in participants with kidney problems, particularly those with severe kidney problems. The study will last about 43 days for each participant.
Conditions Studied
Interventions
- DRUG LY3537982
Study Locations (4)
Florida
- Jacksonville Center for Clinical Research - Jacksonville
- Panax Clinical Research - Miami Lakes
- Orlando Clinical Research Center - Orlando
- Genesis Clinical Research - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07137689
The ClinicalTrials.gov registry entry for NCT07137689 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (68% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which LY3537982 is the first listed.
NCT07137689 reports 4 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07137689 about?
NCT07137689 is a clinical study titled "A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function". The purpose of this study is to help determine the right dose of LY3537982 in participants with kidney problems, particularly those with severe kidney problems. The study will last about 43 days for each participant.
What is the current status of trial NCT07137689?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-08-18. Estimated completion is 2026-03.
What conditions does trial NCT07137689 study?
This clinical trial studies the following conditions: Renal Insufficiency.
What interventions are being tested in trial NCT07137689?
The interventions under investigation include: LY3537982 (DRUG).
Who is sponsoring clinical trial NCT07137689?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07137689 being conducted?
This trial has 4 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
COMPLETED · Phase 1
-
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
COMPLETED · Phase 1
-
Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects
COMPLETED · Phase 1
-
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.